礼来公司近日警示,替尔泊肽(Tirzepatide)在与其它添加剂复合使用时,可能产生的危险药物相互作用目前仍属未知领域。
该声明指出,复合用药的潜在风险尚未经过系统研究,患者若擅自混合使用可能引发不可控的健康隐患。药企强调,此类未经严格测试的用药组合存在安全性空白,亟需医疗监管机构与专业人士关注。
礼来公司近日警示,替尔泊肽(Tirzepatide)在与其它添加剂复合使用时,可能产生的危险药物相互作用目前仍属未知领域。
该声明指出,复合用药的潜在风险尚未经过系统研究,患者若擅自混合使用可能引发不可控的健康隐患。药企强调,此类未经严格测试的用药组合存在安全性空白,亟需医疗监管机构与专业人士关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.